The Second East Coast Academic Screening Symposium, 2011

When:   September 28, 2011
Where:  The Broad Institute
              7 Cambridge Center
              Cambridge MA

How to register: Click here. Registration now open.

On September 28, 2011, the Broad Institute will host the second East Coast Academic Screening Symposium. The event will feature talks on past successes (Session I) and future innovations (Session II) to demonstrate the value of academic probe discovery and development. Organized by the Broad Institute’s Probe Development Center, the symposium seeks to bring together leading academic scientists working on probe discovery and development, and to help train the next generation of chemical biologists by educating graduate students and postdoctoral fellows. Please note: No registration fee will be charged for this symposium.

The one-day event will comprise a morning and afternoon session at the Broad Institute’s 7 Cambridge Center building, followed by a reception.

Session I
Chair: Mike Foley, Broad Institute of MIT and Harvard

Unraveling the genetic mysteries of psychotic illnesses
Ed Scolnick, Broad Institute of MIT and Harvard

HDACs in memory and cognition: Development of isoform selective inhibitors with improved CNS drug properties
Ed Holson, Broad Institute of MIT and Harvard

Diverse phenotypic screens for problems in protein homeostasis: cancer, neurodegeneration, antifungals, and malaria
Susan Lindquist, Whitehead Institute for Biomedical Research and HHMI, Dept. of Biology, MIT

In vivo activity of anti-Trypanosoma cruzi compounds selected from a high throughput screen
Ana Rodriguez, New York University

Identification of Galactokinase Inhibitors: Tools to study galactose metabolism and Classic Galactosemia
Matt Boxer, NIH Chemical Genomics Center

Finding Therapeutics for Motor Neuron Diseases
Lee Rubin, Harvard Stem Cell Institute, Harvard University

Session II
Chair: Michelle Palmer, Broad Institute of MIT and Harvard

Linking genetic features of human cancers to cancer therapeutics.
Stuart Schreiber, Broad Institute of MIT and Harvard

Targeting BCL11A for reactivation of fetal hemoglobin (HbF).
Stuart Orkin, Dana-Farber Cancer Institute

Targeting Prokaryote-Specific Saccharide Biosynthesis in Microbial Pathogens
Barbara Imperiali, Massachusetts Institute of Technology

Targeting Neuropsychiatric Disease Mechanism Using Patient-Specific Stem Cell Models
Stephen Haggarty, Massachusetts General Hospital

Decoding cancer vulnerabilities simultaneously in mixtures of barcoded tumor cell lines with PRISM
Channing Yu, Dana-Farber Cancer Institute

From genotype to phenotype at the chromosome 1p13 cholesterol and heart attack locus: implications for drug development
Kiran Musunuru, Harvard University

This event has been timed to coincide with the Society for Laboratory Automation and Screening (SLAS) Stem Cell Global Symposia 2011 in Boston September 26 and 27.